title: Implementation of a Precision Pathology Program Focused on Oncology-Based Prognostic and Predictive Outcomes.
abstract: Personalized or precision medicine as a diagnostic and therapeutic paradigm was introduced some 10-15 years ago, with the advent of biomarker discovery as a mechanism for identifying prognostic and predictive attributes associated with treatment indication and outcome. While the concept is not new, the successful development and implementation of novel 'companion diagnostics', especially in oncology, continues to represent a significant challenge and is currently at the forefront of smart trial design and therapeutic choice. The ability to determine patient selection for a specific therapy has broad implications including better chances for a positive outcome, limited exposure to potentially toxic drugs and improved health economics. Importantly, a significant step in this paradigm is the role of predictive pathology or the accurate assessment of morphology at the microscopic level. In breast cancer, this has been most useful where histologic attributes such as the classification of tubular and cribriform carcinoma dictates surgery while neoadjuvant studies suggest that patients with lobular carcinoma are not likely to benefit from chemotherapy. The next level of 'personalized pathology' at the tissue-cellular level is the use of 'protein biomarker panels' to classify the disease process and ultimately drive tumor characterization and treatment. The following review article will focus on the evolution of predictive pathology from a subjective, 'opinion-based' approach to a quantitative science. In addition, we will discuss the individual components of the precise pathology platform including advanced image analysis, biomarker quantitation with mathematical modeling and the integration with fluid-based (i.e. blood, urine) analytics as drivers of next generation precise patient phenotyping.
authors.affiliation: Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA. michael.donovan@mssm.edu.
authors.forename: Michael J
authors.identifier: 0000-0003-0772-598X
authors.initials: MJ
authors.lastname: Donovan
authors.affiliation: Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
authors.forename: Carlos
authors.initials: C
authors.lastname: Cordon-Cardo
mesh_terms: D015415:Biomarkers; D001706:Biopsy; D004273:DNA, Neoplasm / Q000097:blood / Q000235:genetics; D055354:Exosomes; D023281:Genomics / Q000379:methods; D006801:Humans; D025202:Molecular Diagnostic Techniques; D009369:Neoplasms / Q000175:diagnosis* / Q000235:genetics / Q000401:mortality / Q000628:therapy; D009360:Neoplastic Cells, Circulating / Q000378:metabolism / Q000473:pathology; D057089:Pathology, Molecular / Q000379:methods*; D010641:Phenotype; D057285:Precision Medicine / Q000379:methods*; D011379:Prognosis
chemical_list: D015415:Biomarkers; D004273:DNA, Neoplasm